Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy.
Related Posts
Bothered by Eye Redness? New Brightening Drops Now Available Without a Prescription
The U.S. Food and Drug Administration (FDA) has approved a new over-the-counter eye drop to treat eye redness. Brytly is the first nonprescription whitening eye […]
‘Groundbreaking Option’ Approved for Rectal Cancer
The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery. The […]
Halloween at Every Stage: Balancing Fun, Safety, and Connection
Halloween is a magical event for people of all ages. Candy, costumes, festive decorations, and trick-or-treating create memories that are cherished for years to come. […]